Chlorite in the treatment of neurodegenerative disease

• US 8,029,826 B2
• Filed: 03/17/2006
• Issued: 10/04/2011
• Est. Priority Date: 02/03/2004
• Status: Active Grant

• Current Assignee: Regents of the University of California (University of California)
• Original Assignee: Regents of the University of California (University of California)
• Inventors: McGrath, Michael S.
• Primary Examiner(s): PAK, JOHN D
• Application Number:
  US11/378,987
• Publication Number:
  US 20060159775A1
• Time in Patent Office: 2,027 Days
• Field of Search: 424/661, 424/665, 514/879
• US Class Current: 424/665
• CPC Class Codes: A61K 33/00 Medicinal preparations containing inorganic active ingredients
• CPC Class Codes: A61K 33/20 Elemental chlorine; Inorganic compounds releasing chlorine
• CPC Class Codes: A61K 33/40 Peroxides
• CPC Class Codes: A61K 47/02 Inorganic compounds
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 21/02 Muscle relaxants, e.g. for tetanus or cramps
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/18 for HIV

Abstract

The invention features methods of treating a macrophage-associated neurodegenerative disease such as amyotrophic lateral sclerosis (ALS), Alzheimer'"'"'s disease (AD), or multiple sclerosis (MS) in a subject by administering chlorite in an amount effective to decrease blood immune cell activation. The invention also features methods of monitoring therapy by assessing blood immune cell activation before and after therapy.

Claims

1. A method of treating Alzheimer'"'"'s disease (AD) in a subject, the method comprising:

administering a pharmaceutically acceptable chlorite salt to a subject having Alzheimer'"'"'s disease (AD), wherein the pharmaceutically acceptable chlorite salt is administered in an amount effective to treat AD in the subject.

2. The method of claim 1, wherein the pharmaceutically acceptable chlorite salt is sodium chlorite.

3. A method of reducing pathologic macrophages in a subject having Alzheimer'"'"'s disease (AD), the method comprising:

administering a pharmaceutically acceptable chlorite salt to a subject having Alzheimer'"'"'s disease (AD), wherein the pharmaceutically acceptable chlorite salt is administered in an amount effective to reduce a level of pathologic macrophages in the subject relative to a level prior to said administering.

4. The method of claim 3, wherein the chlorite salt is sodium chlorite.